ImmunoGen Inc. (NASDAQ:IMGN) Q2 2023 Earnings Conference Call July 31, 2023 8:00 AM ET

Company Participants

Mark Enyedy - President, Chief Executive Officer

Renee Lentini - Chief Financial Officer (interim), Chief Accounting Officer

Isabel Kalofonos - Chief Commercial Officer

Anna Berkenblit - Chief Medical Officer

Michael Vasconcelles - Executive Vice President, Research and Development

Anabel Chan - Head of Investor Relations

Conference Call Participants

John Newman - Canaccord Genuity

Michael Schmidt - Guggenheim

Peter Lawson - Barclays

Etzer Darout - BMO Capital Markets

Boris Peaker - Cowen

Andy Hsieh - William Blair

Kelly Shi - Jefferies

Swayampakula Ramakanth - HC Wainwright

Asthika Goonewardene - Truist

Joe Catanzaro - Piper Sandler

Jonathan Chang - Leerink Partners

Operator

Good morning and welcome to ImmunoGen’s Second Quarter 2023 Financial and Operating Results Conference Call.

Today’s conference is being recorded.

At this time, I’d like to turn the call over to Anabel Chan, Head of Investor Relations. Please go ahead.

Anabel Chan

Good morning and thank you for joining today’s call.

Earlier today, we issued a press release that includes a summary of our recent operating progress and second quarter financial results. This press release, a recording of this call, and an updated corporate deck can be found under the Investors and Media section of immunogen.com.

With me today are Mark Enyedy, our President and CEO, Isabel Kalofonos, our Chief Commercial Officer, Anna Berkenblit, our Chief Medical Officer, and Renee Lentini, our interim CFO. Michael Vasconcelles, our EVP of Research, Development and Medical Affairs will also join us for Q&A. During today’s call, we will review recent progress for the business, our financial results, and highlight upcoming anticipated events.

We will be making forward-looking statements based on our current expectations and beliefs. These statements are subject to risks and uncertainties and our actual results may differ materially. Please consult the risks outlined in our press release issued this morning in the Risk Factors section of our most recent annual report on Form 10-K and quarterly report on Form 10-Q, and in our other SEC filings which are available at SEC.gov and immunogen.com.

With that, I’ll turn over to Mark.

Mark Enyedy

Thanks, Anabel. Good morning, everyone, and thank you for joining us today.

You will have seen this morning’s press release announcing that Anna will be stepping down from her position as ImmunoGen’s Chief Medical Officer to take a well deserved professional hiatus prior to pursuing new opportunities. I would like to take a moment to personally acknowledge and thank her for the essential role she has played in the transformation of this company.